EMFAT
NKTR icon

Emerald Mutual Fund Advisers Trust’s Nektar Therapeutics NKTR Stock Holding History

Emerald Mutual Fund Advisers Trust’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.8M Sell
255,587
-519
-0.2% -$38K 0.63% 74
2026
Q1 		$18.4M Buy
256,106
+2,981
+1% +$170K 0.89% 41
2025
Q4 		$10.7M Buy
253,125
+19,920
+9% +$1.11M 0.52% 86
2025
Q3 		$13.3M Buy
+233,205
New +$7.72M 0.69% 59

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Emerald Mutual Fund Advisers Trust's NKTR Position: Q2 2026 in Review

Emerald Mutual Fund Advisers Trust reduced its Nektar Therapeutics (NKTR) stake by 0.2% in Q2 2026, selling an estimated $38K and leaving 255,587 shares worth $17.8M. The position accounts for 0.63% of the portfolio, ranked #74.

Emerald Mutual Fund Advisers Trust first reported a position in NKTR in Q3 2025 and has held it in 4 quarters since. The position peaked at $18.4M in Q1 2026. 240 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Emerald Mutual Fund Advisers Trust held 255,587 shares of Nektar Therapeutics worth $17.8M as of Q2 2026.
  • Emerald Mutual Fund Advisers Trust sold 519 Nektar Therapeutics shares in Q2 2026, an estimated $38K.
  • Nektar Therapeutics made up 0.63% of Emerald Mutual Fund Advisers Trust's portfolio in Q2 2026, its #74 holding.
  • Emerald Mutual Fund Advisers Trust first reported a position in Nektar Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Emerald Mutual Fund Advisers Trust's Nektar Therapeutics position peaked at $18.4M in Q1 2026.
  • 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Emerald Mutual Fund Advisers Trust's 13F filing for Q2 2026, filed 5 Aug 2026.